Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death

Current treatment options for patients with pancreatic cancer are suboptimal, resulting in a five year survival rate of about 9%. Difficulties with treatment are due to an immunosuppressive, fibrotic tumor microenvironment that prevents drugs from reaching tumor cells, but also to the limited effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastea, Ligia I., Hollant, Laeticia M. A., Döppler, Heike R., Reid, Elizabeth M., Storz, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851150/
https://www.ncbi.nlm.nih.gov/pubmed/31719634
http://dx.doi.org/10.1038/s41598-019-53223-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851150/
https://www.ncbi.nlm.nih.gov/pubmed/31719634
http://dx.doi.org/10.1038/s41598-019-53223-0

Ejemplares similares